top of page
Browse by category
Search
Boston Scientific introduces Endura Weight Loss Solutions
Boston Scientific has introduced its Endura Weight Loss Solutions representing a range of weight loss procedures, including endoscopic...
Lilly's oral GLP-1 orforglipron achieves average of 27.3 lbs weight loss at 72 weeks
Eli Lilly and Company has announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational...
Endoscopic sleeve gastroplasty an effective alternative therapy for MASH
Endoscopic sleeve gastroplasty (ESG) may be an effective alternative therapy in the treatment of patients with metabolic...
Ascletis completes enrolment in US study assessing ASC30 oral GLP-1R agonist
Ascletis Pharma has completed enrolment in its US 13-week Phase IIa study evaluating ASC30, a small molecule oral GLP-1 receptor (GLP-1R)...
GLP-1 implant NPM-115 meets primary endpoint
Vivani Medical has revealed that results from the LIBERATE-1 clinical study, a Phase 1 study of the exenatide GLP-1 implant NPM-115...
12% of Americans have used GLP-1 weight loss drugs
Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to report from...
Browse by tag
bottom of page